[
1. Goldenberg M. Multiple sclerosis review. 2021 Mar;37(3):175-84.
]Search in Google Scholar
[
2. Oh J, Vidal-Jordana A, Montalban X. Multiple sclerosis: clinical aspects. Current Opinion in Neurology: December 2018, 31(6), 752-759. doi: 10.1097/WCO.0000000000000622
]Open DOISearch in Google Scholar
[
3. European multiple sclerosis platform (EMSP) [Internet]. Available from https://www.emsp.org/about-ms/
]Search in Google Scholar
[
4. Hartung DM. Economics and Cost-Effectiveness of Multiple Sclerosis Therapies in the USA. Neurotherapeutics. 2017,14, 1018-1026. https://doi.org/10.1007/s13311-017-0566-3
]Search in Google Scholar
[
5. Naci H, Fleurence R, Birt J, et al. Economic Burden of Multiple Sclerosis. Pharmacoeconomics. 2010, 28, 363-379. https://doi.org/10.2165/11532230-000000000-00000
]Search in Google Scholar
[
6. Newton A, Stica CM. A Comprehensive Cost-Effectiveness Analysis of Treatments for Multiple Sclerosis. Int J MS Care 1 August. 2011; 13(3): 128-135. doi: https://doi.org/10.7224/1537-2073-13.3.128
]Search in Google Scholar
[
7. Gold MR, Siegel JE, Russell LB, Weinstein MS. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996; 18.
]Search in Google Scholar
[
8. Walter E, Berger T, Bajer-Kornek B et al. Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingoli-mod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria. J Med Econ. 2019 Mar;22(3):226-237. doi: 10.1080/13696998.2018.1556668. Epub 2018 Dec 21. PMID: 30522373.
]Open DOISearch in Google Scholar
[
9. Piena MA, Heisen M, Wormhoudt LW et al. Cost-minimization analysis of alemtuzumab compared to fingolimod and natalizumab for the treatment of active relapsing-remitting multiple sclerosis in the Netherlands. J Med Econ. 2018 Oct;21(10):968-976. doi: 10.1080/13696998.2018.1489255. Epub 2018 Jul 9. PMID: 29911917.
]Open DOISearch in Google Scholar
[
10. Hettle R, Harty G, Wong SL. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England. J Med Econ. 2018 Jul;21(7):676-686. doi: 10.1080/13696998.2018.1461630. Epub 2018 Apr 16. PMID: 29618273.
]Open DOISearch in Google Scholar
[
11. Taheri S, Sahraian MA, Yousefi N. Cost-effectiveness of alemtuzumab and natalizumab for relapsing-remitting multiple sclerosis treatment in Iran: decision analysis based on an indirect comparison. J Med Econ. 2019 Jan;22(1):71-84. doi: 10.1080/13696998.2018.1543189. Epub 2018 Nov 20. PMID: 30380350.
]Open DOISearch in Google Scholar
[
12. Giovannoni G, Brex PA, Dhiraj D et al. Glatiramer acetate as a clinically and cost-effective treatment of relapsing multiple sclerosis over 10 years of use within the National Health Service: Final results from the UK Risk Sharing Scheme. Mult Scler J Exp Transl Clin. 2019 Dec 5;5(4):2055217319893103. doi: 10.1177/2055217319893103. PMID: 31839981; PMCID: PMC6896140.
]Open DOISearch in Google Scholar
[
13. Xu Y, Mao N, Chirikov V et al. Cost-effectiveness of Teriflu-nomide Compared to Interferon Beta-1b for Relapsing Multiple Sclerosis Patients in China. Clin Drug Investig. 2019 Mar;39(3):331-340. doi: 10.1007/s40261-019-00750-3. PMID: 30684251; PMCID: PMC6400872.
]Open DOISearch in Google Scholar
[
14. Chirikov V, Ma I, Joshi N et al. Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States. Value Health. 2019 Feb;22(2):168-176. doi: 10.1016/j.jval.2018.08.011. Epub 2018 Dec 6. Erratum in: Value Health. 2019 Jun;22(6):750. PMID: 30711061.
]Open DOISearch in Google Scholar
[
15. Zimmermann M, Brouwer E, Tice JA et al. Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis. CNS Drugs. 2018 Dec;32(12):1145-1157. doi: 10.1007/s40263-018-0566-9. PMID: 30141001.
]Open DOISearch in Google Scholar
[
16. Bowen JD, Kozma CM, Grosso MM et al. A real-world comparison of relapse rates, healthcare costs and resource use among patients with multiple sclerosis newly initiating subcutaneous interferon beta-1a versus oral disease-modifying drugs. Mult Scler J Exp Transl Clin. 2018 Dec 17;4(4):2055217318819031. doi: 10.1177/2055217318819031. PMID: 30574342; PMCID: PMC6299291.
]Open DOISearch in Google Scholar
[
17. Michels RE, De Fransesco M, Mahajan K et al. Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands. Appl Health Econ Health Policy. 2019 Dec;17(6):857-873. doi: 10.1007/s40258-019-00500-8. Erratum in: Appl Health Econ Health Policy. 2020 Feb;18(1):141. PMID: 31444659; PMCID: PMC6885501.
]Open DOISearch in Google Scholar
[
18. Hernandez L, Guo S, Kinter E et al. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States. J Med Econ. 2016 Jul;19(7):684-95. doi: 10.3111/13696998.2016.1157080. Epub 2016 Mar 7. PMID: 26947984.
]Open DOISearch in Google Scholar
[
19. Rezaee M, Izadi S, Keshavarz K et al. Fingolimod versus natalizumab in patients with relapsing remitting multiple sclerosis: a cost-effectiveness and cost-utility study in Iran. J Med Econ. 2019 Apr;22(4):297-305. doi: 10.1080/13696998.2018.1560750. Epub 2019 Jan 8. PMID: 30561242.
]Open DOISearch in Google Scholar
[
20. Melendez-Torres GJ, Auguste P, Armoiry X et al. Clinical effectiveness and cost-effectiveness of beta-interferon and glat-iramer acetate for treating multiple sclerosis: systematic review and economic evaluation. Health Technol Assess. 2017 Sep;21(52):1-352. doi: 10.3310/hta21520. PMID: 28914229; PMCID: PMC5623930.
]Open DOISearch in Google Scholar
[
21. Yang H, Duchesneau E, Foster R et al. Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis. J Med Econ. 2017 Oct;20(10):1056-1065. doi: 10.1080/13696998.2017.1355310. Epub 2017 Jul 31. PMID: 28703659.
]Open DOISearch in Google Scholar
[
22. Poveda JL, Trillo JL, Rubio-Terrps C et al. Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain. Expert Rev Pharmacoecon Outcomes Res. 2020 Jun;20(3):295-303. doi: 10.1080/14737167.2019.1635014. Epub 2019 Jul 25. PMID: 31220959.
]Open DOISearch in Google Scholar
[
23. Hua LH, Hersh CM, Morten P et al. The Impact of Price Reductions After Loss of Exclusivity in a Cost-Effectiveness Analysis: Fingolimod Versus Interferon Beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis. J Manag Care Spec Pharm. 2019 Apr;25(4):490-498. doi: 10.18553/jmcp.2019.25.4.490. PMID: 30917079.
]Open DOISearch in Google Scholar
[
24. Mauskopf J, Fay M, Iyer R et al. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States. J Med Econ. 2016;19(4):432-42. doi: 10.3111/13696998.2015.1135805. Epub 2016 Jan 20. PMID: 26707273.
]Open DOISearch in Google Scholar
[
25. Couto E, Hamidi V, Ringerike T et al. Medicines Used for Multiple Sclerosis – A Health Technology Assessment [Internet]. Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2016 Feb. Report from the Norwegian Institute of Public Health No. 2016-23. PMID: 29553658.
]Search in Google Scholar
[
26. Couto E, Hamidi V, Ringerike T et al. Medicines Used for Multiple Sclerosis – A Health Technology Assessment [Internet]. Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2016 Feb. Report from the Norwegian Institute of Public Health No. 2016-23. PMID: 29553658.
]Search in Google Scholar
[
27. Dashputre AA, Kamal KM, Pawar G. Cost-Effectiveness of Peginterferon Beta-1a and Alemtuzumab in Relapsing-Remitting Multiple Sclerosis. J Manag Care Spec Pharm. 2017 Jun;23(6):666-676. doi: 10.18553/jmcp.2017.23.6.666. PMID: 28530523.
]Open DOISearch in Google Scholar
[
28. Chanatittarat C, Chaikledkaew U, Prayoonwiwat N, et al. Cost-utility analysis of multiple sclerosis treatment in Thailand. Int J Technol Assess Health Care. 2018;34(6):584-592. doi: 10.1017/S0266462318003604. Epub 2018 Dec 18. PMID: 30560761.
]Open DOISearch in Google Scholar
[
29. Alsaqa‘aby MF, Vaidya V, Khreis N et al. Cost-effectiveness of oral agents in relapsing-remitting multiple sclerosis compared to interferon-based therapy in Saudi Arabia. Ann Saudi Med. 2017 Nov-Dec;37(6):433-443. doi: 10.5144/0256-4947.2017.433. PMID: 29229891; PMCID: PMC6074120.
]Open DOISearch in Google Scholar
[
30. Su W, Kansal A, Vicente C et al. The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada. J Med Econ. 2016 Jul;19(7):718-27. doi: 10.3111/13696998.2016.1164174. Epub 2016 Apr 15. PMID: 27080475.
]Open DOISearch in Google Scholar
[
31. Bozkaya D, Livingston T, Migliaccio-Walle K et al. The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis. J Med Econ. 2017 Mar;20(3):297-302. doi: 10.1080/13696998.2016.1258366. Epub 2016 Nov 21. PMID: 27822961.
]Open DOISearch in Google Scholar
[
32. Sawad AB, Seoane-Vazquez E, Rodriguez-Monguio R et al. Cost-effectiveness of different strategies for treatment relapsing-remitting multiple sclerosis. J Comp Eff Res. 2017 Mar;6(2):97-108. doi: 10.2217/cer-2016-0056. Epub 2017 Jan 25. PMID: 28118731.
]Open DOISearch in Google Scholar
[
33. Montgomery SM, Maruszczak MJ, Slater D et al. A discrete event simulation to model the cost-utility of fingolimod and natalizumab in rapidly evolving severe relapsing-remitting multiple sclerosis in the UK. J Med Econ. 2017 May;20(5):474-482. doi: 10.1080/13696998.2016.1276070. Epub 2017 Jan 23. PMID: 28008769.
]Open DOISearch in Google Scholar
[
34. Pinheiro B, Guerreiro R, Costa J et al. Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal. J Med Econ. 2020 May;23(5):484-491. doi: 10.1080/13696998.2020.1717499. Epub 2020 Feb 10. PMID: 31951777.
]Open DOISearch in Google Scholar
[
35. Chevalier J, Chamoux C, Hammqs F et al. Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective. PLoS One. 2016 Mar 17;11(3):e0150703. doi: 10.1371/journal.pone.0150703. PMID: 26987055; PMCID: PMC4795754.
]Open DOISearch in Google Scholar
[
36. Frasco MA, Shih T, Incerti D, et al. Incremental net monetary benefit of ocrelizumab relative to subcutaneous interferon β-1a. J Med Econ. 2017 Oct;20(10):1074-1082. doi: 10.1080/13696998.2017.1357564. Epub 2017 Aug 4. PMID: 28726530.
]Open DOISearch in Google Scholar
[
37. Noon KM, Montgomery SM, Adlard NE et al. When does economic model type become a decisive factor in health technology appraisals? Learning from the expanding treatment options for relapsing-remitting multiple sclerosis. J Med Econ. 2018 Oct;21(10):983-992. doi: 10.1080/13696998.2018.1491007. Epub 2018 Jul 5. PMID: 29923439.
]Open DOISearch in Google Scholar
[
38. Hernandez L, Guo S, Toro-Diaz H et al. Peginterferon beta- 1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis. J Med Econ. 2017 Mar;20(3):228-238. doi: 10.1080/13696998.2016.1247712. Epub 2016 Nov 4. PMID: 27730845.
]Open DOISearch in Google Scholar
[
39. Navarro CE, Ordyñez-Callamand E, Alzate JP. Disease modifying therapies in multiple sclerosis: cost-effectiveness systematic review. Farm Hosp. 2020 Mar 1;44(2):68-76. English. doi: 10.7399/fh.11385. PMID: 32452318.
]Open DOISearch in Google Scholar
[
40. Kobelt G, Jönsson L, Pavelcova M, et al. Real-Life Outcome in Multiple Sclerosis in the Czech Republic. Mult Scler Int. 2019 Feb 18;2019:7290285. doi: 10.1155/2019/7290285. PMID: 30911417; PMCID: PMC6397999.
]Open DOISearch in Google Scholar
[
41. Versteegh M. Impact on the Incremental Cost-Effectiveness Ratio of Using Alternatives to E4-5D in a Markov Model for Multiple Sclerosis. Pharmacoeconomics. 2016 Nov;34(11):1133-1144. doi: 10.1007/s40273-016-0421-0. PMID: 27282692; PMCID: PMC5073108.
]Open DOISearch in Google Scholar
[
42. Lambe T, Duarte R, Mahon J et al. Cladribine Tablets for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics. 2019 Mar;37(3):345-357. doi: 10.1007/s40273-018-0718-2. PMID: 30328051; PMCID: PMC6380198.
]Open DOISearch in Google Scholar
[
43. Lasalvia P, Hernindez F, Castañeda-Cardona C et al. Cost-Effectiveness of Natalizumab Compared With Fingolimod for Relapsing-Remitting Multiple Sclerosis Treatment in Colombia. Value Health Reg Issues. 2020 Dec;23:13-18. doi: 10.1016/j.vhri.2019.08.481. Epub 2020 Jan 28. PMID: 31999987.
]Open DOISearch in Google Scholar
[
44. Kotsopoulos N, Connolly MP, Dort T et al. The fiscal consequences of public health investments in disease-modifying therapies for the treatment of multiple sclerosis in Sweden. J Med Econ. 2020 Aug;23(8):831-837. doi: 10.1080/13696998.2020.1757457. Epub 2020 May 13. PMID: 32400258.
]Open DOISearch in Google Scholar
[
45. Soini E, Joutseno J, Sumelahti ML. Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis. Clin Ther. 2017 Mar;39(3):537-557.e10. doi: 10.1016/j.clinthera.2017.01.028. Epub 2017 Feb 14. PMID: 28209373.
]Open DOISearch in Google Scholar
[
46. Furneri G, Santoni L, Ricella C et al. Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy. BMC Health Serv Res. 2019 Jun 28;19(1):436. doi: 10.1186/s12913-019-4264-1. PMID: 31253138; PMCID: PMC6599237.
]Open DOISearch in Google Scholar
[
47. Klein RW, Dittus RS, Roberts SD, Wilson JR. Simulation Modeling and Health-care Decision Making. Medical Decision Making. 1993;13(4):347-354. doi: 10.1177/0272989X9301300411
]Open DOISearch in Google Scholar
[
48. Relapsing-remitting MS (RRMS). National MS Society. Available from: https://www.nationalmssociety.org/What-is-MS/Types-of-MS/Relapsing-remitting-MS
]Search in Google Scholar
[
49. Yamamoto D, Campbell JD. Cost-Effectiveness of Multiple Sclerosis Disease-Modifying Therapies: A systematic Review of the Literature. Autoimmune Dis. 2012, 2012, Article ID 784364, 13. https://doi.org/10.1155/2012/784364
]Search in Google Scholar
[
50. Hernandez L, O’Donnell M, Postma M. Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations. Pharm Econom. 2018, 36, 1223-1252. https://doi.org/10.1007/s40273-018-0683-9
]Search in Google Scholar
[
51. Navarro CE, Ordyñez-Callamand E, et al. Disease modifying therapies in multiple sclerosis: cost-effectiveness systematic review. Farm Hosp, 2020, 44(2), 68-76.
]Search in Google Scholar
